Цервикон -ДИМ

Quick links

Choose a section

Quick links to important sections

Advertisements

Цервикон -ДИМ

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Цервикон -ДИМ

What is Cervicon-DIM?

Property Description
Active Ingredients Diindolylmethane (DIM) 100 mg
Form & Delivery Vaginal Suppositories (Localized Action)
Type Biologically Active Food Supplement / Nutraceutical
General Class Hormonal Metabolism Support Agent
Origin Derived from Cruciferous Vegetables

What is Cervicon-DIM and What Kind of Product is it?

Cervicon-DIM is a brand-specific product, manufactured by Alcea LLC, and formulated as a biologically active food supplement (nutraceutical) intended to provide nutritional support for women's reproductive health. A key differentiating factor is its formulation as a vaginal suppository, which is designed for localized delivery, ensuring the active substance is concentrated in the target area.

This product is not a prescription medication. Its active compounds are known to influence hormone pathways, placing it in the general category of a hormonal metabolism support agent. This focus on localized delivery and supportive nutritional biochemistry is a specific positioning factor for the product.


Composition and General Goal

Cervicon-DIM's primary active substance is the phytochemical Diindolylmethane (DIM), present at a concentration of 100 mg per suppository. DIM and its precursor, Indole-3-carbinol (I3C), are naturally sourced from cruciferous vegetables. The supplement provides a concentrated and reliable dose of these ingredients that far exceeds what is typically obtained through diet alone.

DIM's role in influencing estrogen metabolism is supported by scientific studies. The general goal of using Cervicon-DIM is to provide supportive care aimed at maintaining the health and resilience of hormone-sensitive tissues, helping the body to promote a favorable cellular environment.

Advertisements

What side effects are possible with Цервикон -ДИМ?

Possible Side Effects and Safety Information

This information reflects the documented safety profile and adverse reactions for Цервикон-ДИМ (Diindolylmethane vaginal suppositories) as established in official regulatory documents and supporting clinical trials. It is not a guide for use or a substitute for medical advice.

Adverse Reactions and Frequency

Adverse events in clinical studies were generally classified as common, with a notable percentage of patients in the active treatment group reporting side effects. The reported reactions were typically mild and non-serious.

System Organ Class Common Adverse Reactions
Reproductive System Disorders Local discomfort, burning, itching, or abnormal discharge at the administration site.
Gastrointestinal Disorders Transient, mild symptoms such as nausea or diarrhea.
General Disorders Discolored urine (considered clinically harmless).

Serious Adverse Reactions (SAEs)

Official regulatory data confirms that no Serious Adverse Events (SAEs) were reported in the clinical trials that established the safety profile of the vaginal suppository formulation.

Safety Restrictions and Limitations

Contraindications are strictly limited to known hypersensitivity or allergy to Diindolylmethane (DIM) or any of the product's excipients. Caution regarding potential drug interactions, such as those that may affect the metabolism of certain co-administered medications like Tamoxifen, is a documented safety consideration.

Population and Duration Safety

There are no explicit safety warnings against prolonged use, as studies have noted the lack of systemic toxicity even with extended administration. Specific safety data for populations such as pregnant or breastfeeding women, or those with severe hepatic or renal impairment, should be consulted in the official prescribing information.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The active substance in Цервикон-ДИМ, Diindolylmethane (DIM), is classified as a biologically active food supplement. Because of this classification, formal regulatory drug labeling does not define specific, codified overdose protocols or mandate explicit instructions for when to seek immediate medical attention. Information regarding severe overexposure is derived from clinical safety studies and official adverse event reporting systems.

Documented physiological manifestations associated with exposure to doses significantly exceeding typical intake (several hundred milligrams daily) include gastrointestinal effects such as nausea, vomiting, and diarrhea. The most significant finding reported in regulatory-cited safety data is the potential for hyponatremia, or severely low serum sodium levels. Severe effects, including elevated blood creatinine and signs of renal distress, have also been documented.

Due to the absence of a specific antidote, management of overexposure is supportive and symptomatic. While no specific threshold mandates help-seeking, medical assessment is warranted following confirmed high exposure or the onset of severe symptoms consistent with documented toxicity. Clinical data suggests that monitoring of serum sodium levels and renal function should be considered by a healthcare professional to manage the documented risks of electrolyte imbalance.

Advertisements

Therapeutic Uses of Цервикон -ДИМ

What Цервикон -ДИМ Treats: Main Uses and Benefits

Цервикон -ДИМ may be part of symptomatic management in situations involving certain distressing symptoms. The medication is commonly used to help with conditions involving inflammatory or irritative processes, and is relevant in contexts marked by increased discomfort or tension. The product is generally applied to address symptoms that appear suddenly or fluctuate, such as those associated with conditions associated with acute or disruptive episodes, including those affecting localized areas subject to inflammatory states.

It is applied in scenarios where additional management of discomfort is required, especially during acute episodes. The product's application is intended to support the patient during difficult episodes by easing distress and providing symptomatic relief that helps patients cope more steadily with symptom fluctuations. This supportive role is critical in clinical settings that involve acute or unstable symptom patterns.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

The product is used for managing symptoms that become more disruptive during flare-ups and provides support that helps ease the overall symptom burden, contributing to improved comfort during these periods.

Regulatory References

  1. Official therapeutic description
Advertisements

Eligibility and Restrictions for Use

The eligibility profile for Цервикон -ДИМ is defined by regulatory guidance concerning its active ingredient, Diindolylmethane (DIM), which acts as a hormonal metabolism modulator.

The product is contraindicated for several key populations. Absolute non-eligibility includes individuals who are pregnant or currently breastfeeding, as official sources confirm insufficient reliable safety data for these states. Use is also strictly contraindicated in patients with or a history of hormone-sensitive conditions, such as breast, uterine, or ovarian cancer, as well as endometriosis or uterine fibroids.

Eligibility is further constrained by regulatory data gaps. The product is not recommended for the pediatric population (children and adolescents) because safety has not been adequately studied in this age group. Similarly, safety is not established for use in individuals with severe hepatic or renal impairment. Conditional use is necessary for patients taking estrogen-based therapies or medications metabolized by certain CYP450 enzyme systems, where regulatory caution is advised.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Цервикон -ДИМ contains Diindolylmethane (DIM) as an active component. The interaction profile for products containing DIM is based on its known metabolic effects, as comprehensive, finalized drug-drug interaction studies from major regulatory bodies for this specific finished product are not widely published.

Interactions are generally classified based on the potential of DIM to influence the body’s metabolic systems or compete with other substances for binding sites. Official regulatory and pharmacopoeial resources indicate the following potential interaction domains:

Interacting Product Category Mechanistic Basis & Constraint
Hormone-Containing Medications (e.g., Estrogen, Oral Contraceptives) DIM may have complex effects on estrogen metabolism and hormone-receptor activity, which could theoretically interfere with the effectiveness of exogenous estrogen or hormone replacement therapy.
Cytochrome P450 1A2 (CYP1A2) Substrates DIM has been observed to alter the activity of certain liver enzymes, such as CYP1A2. The concurrent use of drugs primarily metabolized by this enzyme may require monitoring, as DIM could potentially reduce the concentration and effect of the co-administered medication.
Diuretic Drugs (Water Pills) Caution is advised with Diuretics, as the combined effect with DIM may potentially lead to overly decreased sodium levels in the body (hyponatremia).

The official interaction profile is structured around these metabolic and hormonal effects. Patients using medications critical to their health, especially those metabolized by the liver’s CYP enzymes or those involved in hormone therapy, should consult with a healthcare professional before use. This information reflects documented pharmacological potential and is not a comprehensive list of all possible interactions.

Advertisements

Mechanism of Action

The active component of Цервикон-ДИМ (Cervikon-DIM) is Diindolylmethane (DIM), which acts through multiple mechanistic domains to influence cellular processes.

Influence on Estrogen Metabolizing Enzymes

This domain covers the drug's effect on cytochrome P450 enzymes like CYP1A1, which mediate the metabolism of estrogens. This action alters the ratio of estrogen metabolites, increasing the 2-hydroxyestrone pathway relative to the 16 alpha-hydroxyestrone pathway.

Interaction with Cell Cycle and Apoptosis Pathways

DIM engages mechanisms that influence the expression of oncogenic viral transcripts, specifically HPV E6 and E7. These effects culminate in the induction of molecular markers associated with cell cycle arrest and apoptosis (programmed cell death).

Influence on Mediators of the Immune System

The drug acts within domains involving the expression of key immune system components, leading to the measurable elevation of specific cytokines such as Interferon-Gamma ( IFN-gamma) and Interleukin-12 (IL-12). This cascade influences the expression profiles of key immune cytokines.

Advertisements

Dosage and Administration Information

The usage protocol for Цервикон -ДИМ is defined by its specific dosage form and the properties of its active component, Diindolylmethane (DIM). The product is formulated exclusively as a vaginal suppository, establishing the administration route as strictly intravaginal for localized action. This method of delivery requires no special preparation steps, consistent with self-administration in an outpatient setting.

The standard regimen involves applying one 100 mg suppository once daily. This establishes a continuous daily administration pattern, which is characteristic of the product's supportive role. While the base dose is 100 mg, the maximum daily dose for DIM in adults is capped at 200 mg, which would correspond to a divided dose regimen.

In terms of duration, the usage pattern is typically long-term, reflecting the need for sustained supportive care. Courses of use are commonly defined to last for an extended period, generally ranging from 3 to 6 months of continuous daily application.

Usage instructions specify that this product is intended only for Adults 18 years and older. No specific dose adjustments for groups like older adults or those with organ impairment are mandated for this supplement type, reinforcing the straightforward nature of its labeled use. This entire protocol ensures the application adheres to both the localized nature of the dosage form and the established limits for Diindolylmethane.

Advertisements

Recent Clinical Evidence

Research on the compound Diindolylmethane (DIM), the active component of Цервикон-ДИМ, has primarily focused on its use in patients with Cervical Intraepithelial Neoplasia (CIN) Grade 1–2, often associated with Human Papillomavirus (HPV). Studies examine whether local administration of the compound is associated with changes in the progression of these low-grade cervical abnormalities.

Efficacy in CIN 1–2

A double-blind, randomized, placebo-controlled multicenter clinical trial investigated the effect of DIM-containing vaginal suppositories in women diagnosed with CIN 1–2. The primary endpoint was the complete histological regression of the cervical lesion after 90–180 days of treatment.

Treatment Group Complete Regression Rate (95% CI)
High Dose DIM 100.0% (82.35–100.00%)
Low Dose DIM 90.5% (69.62–98.83%)
Placebo 61.1% (35.75–82.70%)

These findings suggest that a higher proportion of patients in the active DIM groups experienced lesion regression compared to the placebo group. Separately, a large randomized trial of oral DIM supplementation for low-grade cytological abnormalities did not find a significant difference in cell changes or HPV infection rates after six months.

Safety and Tolerability

Clinical trials have generally indicated that the local administration of DIM vaginal suppositories is well-tolerated. In one safety study involving 90 patients with CIN 1–2, a low number of adverse events (AEs) were reported in both the active DIM and placebo groups. The reported AEs were described as being of mild intensity, and no serious adverse events were registered in any group. The favorable safety profile was observed during treatment periods lasting up to 160 days.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Цервикон -ДИМ (FAQ)

Q: What health issues is Цервикон -ДИМ used for?

A: The product is officially classified as a nutraceutical designed to provide supportive care aimed at maintaining the health and resilience of hormone-sensitive tissues. The active ingredient, Diindolylmethane (DIM), is noted in research for its role in estrogen metabolism and its investigation in conditions such as Cervical Intraepithelial Neoplasia (CIN).


Q: Is Цервикон -ДИМ a hormonal treatment?

A: No. Official classifications describe the active component as a substance that helps to support and promote healthy estrogen metabolism and balance, rather than being a hormone itself. It acts as a modulator that influences how the body processes its natural estrogen.


Q: What is the difference between Цервикон -ДИМ and other similar treatments?

A: The product's key difference, as described in official information, is its formulation as a vaginal suppository. This design allows for localized delivery, ensuring the active substance is concentrated in the target area, unlike other products containing Diindolylmethane (DIM) that are taken orally.


Q: Can I use painkillers or antibiotics at the same time as Цервикон -ДИМ?

A: Studies on the active component, Diindolylmethane (DIM), have observed that it can influence certain liver enzymes (such as CYP450 1A2 and 3A4). These enzymes are responsible for breaking down many other medications, including some antibiotics and painkillers. A healthcare professional should be consulted when co-administered drugs that are metabolized by these systems are being considered.


Q: Is it normal to experience mild irritation after application?

A: While the product is generally considered well-tolerated in studies, the side effect profile for the active ingredient, DIM, includes possible local reactions. These have been described as reactions such as burning, vaginal itching, and hives (urticaria), typically noted as being of mild intensity.


Q: What are the most commonly reported side effects?

A: According to official regulatory information, the most common reported side effects for the active component (DIM) when taken in recommended doses include headache, nausea, vomiting, gas, and diarrhea. Users may also notice harmless changes in urine color.


Q: Does Цервикон -ДИМ affect the menstrual cycle?

A: Official reports of side effects indicate possible changes in menstrual cycles in women. These effects are typically associated with higher doses of the active ingredient, Diindolylmethane (DIM).


Q: Is it possible to experience fatigue while using Цервикон -ДИМ?

A: Yes, official data on the active ingredient indicate that among the possible side effects, some patients have reported experiencing fatigue or a feeling of fogginess.


Q: Are there any specific foods or supplements that interact with Цервикон -ДИМ?

A: The active ingredient, Diindolylmethane (DIM), is naturally derived from cruciferous vegetables. While no mandatory dietary changes are stipulated, taking the product with food is sometimes noted to help minimize mild stomach upset.


Q: Does the time of day matter when using Цервикон -ДИМ?

A: The product's usage protocol specifies a continuous once daily administration. General guidance related to the active ingredient (DIM) has noted the timing of use, suggesting that use earlier in the day may be considered to potentially minimize sleep disruption.


Q: Can Цервикон -ДИМ cause headaches or dizziness?

A: Yes, according to official side effect profiles for the active component, Diindolylmethane (DIM), both headache and dizziness are listed among the possible reported side effects.


Q: Is it normal if I don't feel any immediate difference after starting treatment?

A: Yes, based on the usage protocol, the expected duration of treatment is typically long-term, often ranging from 3 to 6 months. For this reason, an immediate or rapid sensation of effect is not the general expectation.


Q: Can Цервикон -ДИМ be used by women going through menopause?

A: Since the active ingredient (DIM) is a hormonal metabolism support agent, official information suggests it may be suitable for women going through perimenopause or menopause. Eligibility is defined for adults 18 years and older, provided there are no other contraindications, such as a history of hormone-sensitive conditions.


Q: Is there any risk of overdose with Цервикон -ДИМ?

A: Official safety data suggests that taking doses of the active ingredient significantly above the established maximum daily dose is not recommended and may be associated with increased risk of side effects. Very high doses have been associated with potential side effects such as abnormally reduced sodium levels in the body.


Q: Can using Цервикон -ДИМ affect the results of other medical tests?

A: The active ingredient, Diindolylmethane (DIM), is known to influence the metabolism of estrogens. Official documentation indicates that its use is associated with measurable changes in the urinary estrogen profile, which may affect the interpretation of certain related medical tests.


Q: Are there different strengths or dosages of Цервикон -ДИМ available?

A: The product is manufactured as a 100 mg suppository. Although the official maximum daily amount for the active ingredient (DIM) in adults is up to 200 mg, the product is manufactured only in the 100 mg strength.


Q: What are the signs of a severe allergic reaction to look out for?

A: A serious adverse event is defined in regulatory terms as an outcome such as death, a life-threatening experience, or the need for inpatient hospitalization. This information is required to be reported to manufacturers according to general guidance for dietary supplements.


Q: Why is this drug sometimes used in conjunction with other treatments?

A: The active ingredient, Diindolylmethane (DIM), is known to support immune function and influence liver enzyme activity. This mechanism is the basis for its potential use in conjunction with other treatments for supportive care, as noted in official studies.

Advertisements

How should Цервикон -ДИМ be stored and disposed of?

Storage and Disposal Requirements

This information is based on the official storage and handling instructions for Цервикон-ДИМ suppositories, which must be strictly followed to maintain the product's quality and two-year shelf life.

Storage Component Official Requirement
Temperature Range Store at a temperature below 25 C.
Environmental Control Store in a dry, dark place and protect from light.
Handling Prohibition The medicine must not be frozen and must remain in its original packaging.
Child Safety Keep out of the sight and reach of children.

Disposal of unused or expired suppositories must be carried out in accordance with local regulations for pharmaceutical waste, ensuring the product is not discarded into household trash or wastewater unless specifically permitted by those guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Цервикон -ДИМ found in:

A-Z Index: